Source: startupticker

Calypso Biotech: Clinical progression and 8M funding for Calypso Biotech

Following the launch of its phase I clinical trials for lead candidate CALY-002, Merck Serono spin-off, Calypso Biotech, has secured €8 million in a Series A extension round, bringing the total capital raised to €28 million. The funds will accelerate clinical developments.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Alain Vicari's photo - Co-Founder & CEO of Calypso Biotech

Co-Founder & CEO

Alain Vicari

CEO Approval Rating

90/100

Read more